← Back to Search

Extended CTA for Ischemic Stroke Detection (DAYLIGHT Trial)

N/A

Recruiting

Led By Luciano Sposato, MD

Research Sponsored by London Health Sciences Centre Research Institute and Lawson Research Institute of St. Joseph's

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up through study completion, an average of 1 year

Awards & highlights

No Placebo-Only Group

Summary

This trial will help us better understand the role of LAA thrombi in ESUS and identify risk factors for stroke recurrence. #ESUS #CryptogenicStroke #TEE #CTA #LAAThrombi

Who is the study for?

The DAYLIGHT trial is for adults who come to the emergency department or stroke clinic with a suspected stroke or mini-stroke. They don't need a confirmed diagnosis to join. However, pregnant individuals, those with severe kidney disease, past or active cancers of the head, neck, or chest; allergies to iodine-based contrast agents; or without vein access for IV contrast are excluded.

What is being tested?

This study tests if an extended CT angiography (eCTA) can better detect blood clots in the heart's left atrial appendage compared to standard CT angiography (sCTA). Both groups will receive usual care for stroke evaluation but one group will have additional imaging extending below the carina.

What are the potential side effects?

Potential side effects mainly relate to CTA and may include reactions to contrast dye like rash or itching, kidney function impairment especially in those already at risk, and discomfort from lying still during scanning.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ through study completion, an average of 1 year

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~through study completion, an average of 1 year

This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of 1 year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Primary Efficacy Outcome: The proportion of participants with a confirmed or "highly suspected" newly diagnosed cardioaortic thrombus

Secondary study objectives

Secondary Efficacy Outcome 1: The proportion of participants diagnosed with a cardio-aortic embolic source that has an available guideline-supported treatment including thrombi, vegetations, and tumors.

Secondary efficacy outcome 2: The proportion of participants diagnosed with a cardio-aortic embolic source known to increase the risk of stroke.

Secondary efficacy outcome 3: The proportion of participants diagnosed with a cardio-aortic embolic source resulting in the initiation of a new secondary prevention treatment other than antiplatelet therapy.

Other study objectives

Primary Safety Outcome 1: door to sCTA time vs door to eCTA

Secondary Safety Outcome 1: Door-to-needle

Secondary Safety Outcome 2: Door-to-groin puncture

+5 more